Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial

Autor: Lawrence A. Leiter, Stephen C. Bain, Irene Hramiak, Esteban Jódar, Sten Madsbad, Theis Gondolf, Thomas Hansen, Ingrid Holst, Ildiko Lingvay

Publikováno v: Cardiovascular Diabetology, Vol 18, Iss 1, Pp 1-12 (2019)

Abstract Background The SUSTAIN 6 trial demonstrated that once-weekly semaglutide (0.5 and 1.0 mg) significantly reduced major adverse cardiovascular (CV) events (MACE) vs placebo in subjects with type 2 diabetes (T2D) and high CV risk. The effects o

Externí odkaz: https://doaj.org/article/fe71e6d6a8614c3f877bea8458d69b7a

P6271The effect of semaglutide once weekly on MACE and blood pressure by race and ethnicity: SUSTAIN 6 post hoc analysis

Autor: Ingrid Holst, Cyrus Desouza, Theis Gondolf, Rosangela Rea, Stephen C. Bain, Torben Hansen, Jochen Seufert

Publikováno v: European Heart Journal. 40

Background In SUSTAIN 6, subcutaneous semaglutide once weekly added to standard of care significantly reduced major adverse cardiovascular events (MACE: non-fatal myocardial infarction, non-fatal stroke or death) vs placebo over 2 years in T2D subjec

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::06049e7e7864285c0d21fbf9fa52314d
https://doi.org/10.1093/eurheartj/ehz746.0870

FP482EGFR LOSS WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUE TREATMENT: DATA FROM SUSTAIN 6 AND LEADER

Autor: Kenneth W. Mahaffey, Stephen C. Bain, John B. Buse, George L. Bakris, Johannes F.E. Mann, Vlado Perkovic, Steven P. Marso, Thomas Idorn, Bernard Zinman, Peter Rossing, Nanna L. Lausvig, Michael A. Nauck, Theis Gondolf, Richard E. Pratley

Publikováno v: Nephrology Dialysis Transplantation. 34

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c03e79f44fea90712a8e24721226ef12
https://doi.org/10.1093/ndt/gfz106.fp482

Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes:A post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial

Autor: Ingrid Holst, Stephen C. Bain, Lawrence A. Leiter, Irene Hramiak, Thomas Kruse Hansen, Esteban Jódar, Theis Gondolf, Sten Madsbad, Ildiko Lingvay

Publikováno v: Leiter, L A, Bain, S C, Hramiak, I, Jódar, E, Madsbad, S, Gondolf, T, Hansen, T, Holst, I & Lingvay, I 2019, ' Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes : A post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial ', Cardiovascular Diabetology, vol. 18, 73 . https://doi.org/10.1186/s12933-019-0871-8
Cardiovascular Diabetology
Cardiovascular Diabetology, Vol 18, Iss 1, Pp 1-12 (2019)

Background The SUSTAIN 6 trial demonstrated that once-weekly semaglutide (0.5 and 1.0 mg) significantly reduced major adverse cardiovascular (CV) events (MACE) vs placebo in subjects with type 2 diabetes (T2D) and high CV risk. The effects of gender,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6b7ff00c7185e99d2d7c052fb05fdfd
https://curis.ku.dk/portal/da/publications/cardiovascular-risk-reduction-with-onceweekly-semaglutide-in-subjects-with-type-2-diabetes(c3249e3b-9fa3-4a17-87b3-a5c2d5e46dc6).html

A randomized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5)

Autor: Tadej Battelino, J. Hans DeVries, Theis Gondolf, Mark L. Evans, David C. Klonoff, A. Hyseni, Eric Renard, Wendy Lane, Tina Graungaard, Hans-Peter Kempe

Publikováno v: Diabetes, Obesity and Metabolism
Diabetes, Obesity and Metabolism, 2018, pp.961-967. ⟨10.1111/dom.13610⟩
Diabetes, Obesity and Metabolism, Wiley, 2018, ⟨10.1111/dom.13610⟩
Diabetes, Obesity & Metabolism
Diabetes, obesity & metabolism, 21(4), 961-967. Wiley-Blackwell

International audience; Aim: To evaluate the efficacy and safety of fast-acting insulin aspart (faster aspart) vs insulin aspart (IAsp) used in continuous subcutaneous insulin infusion (CSII) in participants with type 1 diabetes (T1D).Materials and m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91a00426d97f8efb34bbcfa9890d723c
https://hal.umontpellier.fr/hal-02071091